PREMIERING NOW: Devin Nunes: Congress Must Investigate DOJ, FBI, and Beyond in November | Kash’s Corner

Click here to read the full article.

This episode will premiere on Friday, Aug. 5, at 8 p.m. ET.   

On this special episode of Kash’s Corner, Kash Patel sits down with his former boss, Congressman Devin Nunes, now CEO of Trump Media & Technology Group, to reflect on their time in Washington and what it was like trying to expose egregious misconduct in the Department of Justice, FBI, and beyond.

“This was something that we never knew could exist—that you could somehow get a contractor that could become politicized to go out and use the powers of the state to essentially spy on your political opponents … That’s what happened,” says Nunes.

They discuss lessons from the Michael Sussmann trial, what’s coming next in the Igor Danchenko trial, and how Nunes sees the Department of Justice and other agencies being held accountable if the gavel changes hands.

“There’s going to have to be an investigation like none that’s ever been done before, directly at the Department of Justice and everything below,” argues Nunes.

Disclaimer: Kash Patel is a board member of Trump Media & Technology Group, the company that owns Truth Social. 

Subscribe to the American Thought Leaders newsletter so you never miss an episode.

* Click the “Save” button below the video to access it later on “My List.”

Follow EpochTV on social media:

Twitter: https://twitter.com/EpochTVus
Rumble: https://rumble.com/c/EpochTV
Truth Social: https://truthsocial.com/@EpochTV

Gettr: https://gettr.com/user/epochtv
Facebook: https://www.facebook.com/EpochTVus
Gab: https://gab.com/EpochTV
Telegram: https://t.me/EpochTV

Continue reading here.

Scroll down for comments and share your thoughts!

What do you think?

Leave a Reply

Your email address will not be published.

GIPHY App Key not set. Please check settings

Anomaly in Employment Statistics Grows: How Many Americans Actually Work?

[PREMIERING 9 PM ET] Dr. Malone: 29,790 Official Deaths Linked to Vaccine in VAERS Likely a Tiny Fraction of True Number (Part 1)